Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab-Reference-Cited by-同舟云学术

Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab

Published:2014-03-13 Issue:12 Volume:120 Page:1780-1786
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pant Shubham¹,Martin Ludmila K.²,Geyer Susan³,Wei Lai³,Van Loon Katherine⁴,Sommovilla Nilli⁵,Zalupski Mark⁶,Iyer Renuka⁷,Fogelman David⁸,Ko Andrew H.⁴,Bekaii-Saab Tanios²

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine; University of Oklahoma; Oklahoma City Oklahoma

2. Division of Medical Oncology, Department of Internal Medicine; The Ohio State University; Columbus Ohio

3. Department of Biostatistics; The Ohio State University; Columbus Ohio

4. Division of Hematology and Oncology, Department of Medicine; University of California at San Francisco; San Francisco California

5. Department of Internal Medicine; Mount Sinai School of Medicine; New York City New York

6. Department of Internal Medicine; University of Michigan; Ann Arbor Michigan

7. Department of Medicine; Roswell Park Cancer Institute; Buffalo New York

8. Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28648/fullpdf

Reference27 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil;Burris;Eur J Cancer,1997

3. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

4. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Hoff;N Engl J Med,2013

5. Genentech 2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian;Cancers;2024-06-26

2. Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer;Acta Oncologica;2021-09-06

3. A new prognostic model for predicting 30-day mortality in acute oncology patients;Expert Review of Anticancer Therapy;2021-07-30

4. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis;Frontiers in Oncology;2021-05-27

5. Controlling Nutritional Status score is superior to Prognostic Nutritional Index score in predicting survival and complications in pancreatic ductal adenocarcinoma: a Chinese propensity score matching study;British Journal of Nutrition;2020-06-29